REGEN BIOLOGICS
ReGen Biologics, Inc. designs, develops, manufactures, and markets medical devices for the repair and generation of soft tissue in humans, primarily for orthopedic applications. The company’s proprietary collagen matrix technology includes applications in orthopedics, general surgery, spine, cardiovascular, and drug delivery. Its products include Menaflex collagen meniscus implant device, for use in surgical procedures for the reinforcement and repair of soft tissue injuries of the medial meni... scus; and SharpShooter Tissue Repair System, an instrument that allows surgeons to place needles in hard-to-reach locations of the meniscus. The company sells its products in the United States, the European Union, the Republic of South Africa, Canada, Australia, Chile, and Japan. ReGen Biologics, Inc. was founded in 1987 and is headquartered in Hackensack, New Jersey. On April 8, 2011, ReGen Biologics, Inc. filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware. The plan was later approved as Chapter 11 liquidation on October 14, 2011.
REGEN BIOLOGICS
Industry:
Biotechnology Developer Platform Health Care Manufacturing
Founded:
1987-01-01
Address:
Hackensack, New Jersey, United States
Country:
United States
Website Url:
http://www.regenbio.com
Total Employee:
1+
Status:
Active
Contact:
201-651-5140
Total Funding:
7.05 M USD
Technology used in webpage:
Content Delivery Network CSC Global DNS Network Solutions Ads WidgetBox
Similar Organizations
Anika Therapeutics
Anika Therapeutics, Inc. develops, manufactures, and commercializes therapeutic products for tissue protection, healing, and repair. Its
Current Employees Featured
Founder
Official Site Inspections
http://www.regenbio.com
- Host name: 165.160.13.20
- IP address: 165.160.13.20
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "ReGen Biologics"
Management Team - REGENXBIO
Ms. Fritsch brings over two decades of experience in research, development and human resources in the biopharmaceutical industry to REGENXBIO. For the past decade, Ms. Fritsch has been a leader in different organizations where she …See details»
A new way to treat disease is on the horizon.
REGENXBIO is seeking to improve lives through the curative potential of gene therapy. Our NAV® Technology Platform has ushered in a new era of gene therapy innovation. Learn More. Patients & Families. Envisioning a brighter …See details»
Leadership Team - REGENXBIO
Curran M. Simpson is the President and Chief Executive Officer and member of the Board of Directors at REGENXBIO. Mr. Simpson previously served as the Company’s Chief Operating …See details»
Board of Directors - REGENXBIO
Ken Mills served as the founding President and Chief Executive Officer of REGENXBIO from 2009-2024, and is now Chairman of the Board of Directors. Mr. Mills led REGENXBIO’s initial …See details»
REGENXBIO - Crunchbase Company Profile & Funding
REGENXBIO closed its last funding round on Mar 6, 2024 from a Post-IPO Equity round. Who are REGENXBIO 's competitors? Alternatives and possible …See details»
REGENXBIO - Funding, Financials, Valuation & Investors
REGENXBIO is registered under the ticker NASDAQ:RGNX . Their stock opened with $22.00 in its Sep 8, 2015 IPO. Stock Symbol NASDAQ:RGNX ; Valuation at IPO $492M; Money Raised …See details»
REGENXBIO - Contacts, Employees, Board Members, Advisors
Organization. REGENXBIO . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 16. Number of Board …See details»
REGENXBIO’s Research and Development …
Mar 1, 2024 REGENXBIO was also eligible to receive the Partnership for Workforce Quality grant, aiding in meeting training requirements. Additionally, Montgomery County provided a …See details»
Regenxbio Company Profile - Office Locations, Competitors ... - Craft
Oct 29, 2024 Regenxbio has 5 employees at their 1 location and $83.33 m in annual revenue in FY 2024. See insights on Regenxbio including office locations, competitors, revenue, …See details»
Nippon Shinyaku and REGENXBIO Enter into an Exclusive …
Jan 14, 2025 For RGX-121, REGENXBIO has received Fast Track Designation, Rare Pediatric Disease Designation, Regenerative Medicine Advanced Therapy Designation, and Orphan …See details»
RegenxBio Inc Executive & Employee Information - GlobalData
The following section provides information on RegenxBio Inc’s senior management, executives, CEO and key decision makers and their roles in the organization. For more insight into …See details»
Who We Are - REGENXBIO
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Our gene therapy product candidates are designed to …See details»
The Silverstein Foundation, REGENXBIO, and OrbiMed Launch
The Silverstein Foundation is a 501(c)(3) non-profit organization founded in 2017 focused on investing in cutting edge research with the goal of discovering new therapies for the treatment …See details»
REGENXBIO Reports Fourth Quarter and Full Year 2024 Financial …
Mar 13, 2025 Refer to the "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of REGENXBIO's Annual Report on …See details»
Press Releases │ NIPPON SHINYAKU CO., LTD.
Jan 14, 2025 For RGX-121, REGENXBIO has received Fast Track Designation, Rare Pediatric Disease Designation, Regenerative Medicine Advanced Therapy Designation, and Orphan …See details»
RegenxBio, Inc. (RegenxBio, Inc.) - 药物管线_专利_临床试验_投融营 …
了解RegenxBio, Inc. (RegenxBio, Inc.)公司的药物管线，治疗领域，技术平台，以及它的19项临床试验, 199篇新闻和55篇文献，疾病领域:神经系统疾病，内分泌与代谢疾病，肿瘤，免疫系统 …See details»
Pioneers in Gene Therapy - REGENXBIO
Since our founding in 2009, REGENXBIO has been a leader in the gene therapy field, driven by our ongoing commitment to develop gene therapies that improve treatment options for people …See details»
REGENXBIO Announces Closing of Strategic Partnership with …
ROCKVILLE, Md., March 4, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the closing of its previously announced strategic partnership with Nippon …See details»
Pioneering Aging Treatments | ReGENE
At ReGENE, we’re focused on developing therapies to prevent and treat aging-associated non-communicable diseases. We believe that by understanding the intricate biological processes …See details»
Mission & Values - REGENXBIO
REGENXBIO is on a mission to improve lives through the curative potential of gene therapy. Gene therapy has the potential to address the underlying cause of disease, providing single …See details»